Biohaven (NYSE:BHVN) Trading Up 7.1% – Time to Buy?

Biohaven Ltd. (NYSE:BHVN)’s share price was up 7.1% during trading on Monday . The stock traded as high as $10.06 and last traded at $10.3150. Approximately 76,697 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 2,390,875 shares. The stock had previously closed at $9.63.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. The Goldman Sachs Group upgraded Biohaven to a “strong-buy” rating in a research report on Friday, February 6th. Royal Bank Of Canada raised their price objective on Biohaven from $22.00 to $23.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 3rd. Raymond James Financial restated a “strong-buy” rating on shares of Biohaven in a research report on Monday, March 9th. Canaccord Genuity Group assumed coverage on Biohaven in a research report on Monday, April 13th. They set a “buy” rating and a $21.00 price objective for the company. Finally, HC Wainwright lowered their price objective on Biohaven from $11.00 to $10.00 and set a “neutral” rating for the company in a research report on Wednesday, March 4th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $22.53.

Biohaven Stock Performance

The firm has a market capitalization of $1.53 billion, a P/E ratio of -1.46 and a beta of 1.32. The stock has a fifty day simple moving average of $9.91 and a two-hundred day simple moving average of $11.07. The company has a debt-to-equity ratio of 4.59, a current ratio of 3.18 and a quick ratio of 3.18.

Biohaven (NYSE:BHVN) last issued its earnings results on Monday, March 2nd. The company reported ($1.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.01. On average, research analysts predict that Biohaven Ltd. will post -2.98 EPS for the current year.

Institutional Investors Weigh In On Biohaven

Hedge funds have recently added to or reduced their stakes in the business. Integral Health Asset Management LLC increased its holdings in Biohaven by 116.7% in the third quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $9,756,000 after purchasing an additional 350,000 shares in the last quarter. Capital Research Global Investors increased its holdings in Biohaven by 108.9% in the third quarter. Capital Research Global Investors now owns 1,011,530 shares of the company’s stock worth $15,183,000 after purchasing an additional 527,337 shares in the last quarter. Aberdeen Group plc acquired a new stake in Biohaven in the fourth quarter valued at approximately $7,829,000. SG Americas Securities LLC grew its stake in Biohaven by 291.8% in the fourth quarter. SG Americas Securities LLC now owns 105,518 shares of the company’s stock valued at $1,191,000 after acquiring an additional 78,585 shares during the period. Finally, Readystate Asset Management LP grew its stake in Biohaven by 14.1% in the third quarter. Readystate Asset Management LP now owns 377,119 shares of the company’s stock valued at $5,661,000 after acquiring an additional 46,587 shares during the period. 88.78% of the stock is currently owned by institutional investors.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.